Evidence map›Paper›PMID 38640424›Full record

ArticleCell cycle (Georgetown, Tex.)2024

Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.

Jiajun Xu, Raghad Abdulsalam Khaleel, Haider Kamil Zaidan, Ahmed Faisal Mutee, Khaled Fahmi Fawy, Anita Gehlot, Alaa Hashim Abbas, José Luis Arias Gonzáles, Ali H Amin, Maribel Carmen Ruiz-Balvin and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Discovery of insectFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 9 countries.

Jiajun XuCollege of Veterinary & Life Sciences, the University of Glasgow, Glasgow, UK.
Raghad Abdulsalam KhaleelCollege of Medicine, University of Al-Iraqia, Baghdad, Iraq.
Haider Kamil ZaidanNursing College, Al-Mustaqbal University, Hillah, Babylon, Iraq.
Ahmed Faisal MuteeDepartment of Pharmacy, Al-Noor University College, Nineveh, Iraq.
Khaled Fahmi FawyDepartment of Chemistry, Faculty of Science, King Khalid University, Abha, Saudi Arabia.
Anita GehlotUttaranchal Institute of Technology, Uttaranchal University, Dehradun, India.
Alaa Hashim AbbasCollege of Dentistry, Al-Mustaqbal University, Babylon, Iraq.
José Luis Arias GonzálesDepartment of Social Sciences, Faculty of Social Studies, University of British Columbia, Vancouver, Canada.
Ali H AminZoology Department, Faculty of Science, Mansoura University, Mansoura, Egypt.
Maribel Carmen Ruiz-BalvinUniversidad Peruana los Andes, Huancayo, Peru.
Shima ImannezhadDepartment of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abolfazl BahramiBiomedical Center for Systems Biology Science Munich, Ludwig-Maximilians-University, Munich, Germany.
Reza Akhavan-SigariDepartment of Neurosurgery, University Medical Center Tuebingen, Tuebingen, Germany.
University of Babylon · IQAl-Nisour University College · IQIraqi University · IQKing Khalid University · SALos Andes Peruvian University · PELudwig-Maximilians-Universität München · DEMansoura University · EGMashhad University of Medical Sciences · IRUniversity of British Columbia · CAUniversity of Glasgow · GBUniversity of Tübingen · DEUttaranchal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin-converting enzyme 2 (ACE2) is identified as the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing global coronavirus disease-2019 (COVID-19) pandemic. This study aimed to elucidate potential therapeutic avenues by scrutinizing approved drugs through the identification of the genetic signature associated with SARS-CoV-2 infection in individuals with asthma. This exploration was conducted through an integrated analysis, encompassing interaction networks between the ACE2 receptor and common host (co-host) factors implicated in COVID-19/asthma comorbidity. The comprehensive analysis involved the identification of common differentially expressed genes (cDEGs) and hub-cDEGs, functional annotations, interaction networks, gene set variation analysis (GSVA), gene set enrichment analysis (GSEA), and module construction. Interaction networks were used to identify overlapping disease modules and potential drug targets. Computational biology and molecular docking analyzes were utilized to discern functional drug modules. Subsequently, the impact of the identified drugs on the expression of hub-cDEGs was experimentally validated using a mouse model. A total of 153 cDEGs or co-host factors associated with ACE2 were identified in the COVID-19 and asthma comorbidity. Among these, seven significant cDEGs and proteins - namely,

Indexed as

Angiotensin-Converting Enzyme 2AsthmaCOVID-19COVID-19 Drug TreatmentDrug RepositioningAnimalsComorbidityComputational BiologyGene Regulatory NetworksHumansMiceMicroRNAsMolecular Docking SimulationSARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2MicroRNAsACE2asthmacomorbiditiesdrug repurposinghub-cDEGsSARS-CoV-2

Identifiers

PMID38640424
PMCPMC11529202
OpenAlexW4394947209

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.